Key Points

• Gain Therapeutics (NASDAQ:GANX) presented new interim Phase 1b data showing stable MDS-UPDRS scores after 150 days of treatment with GT-02287 in Parkinson’s disease patients.

• The company also reported stronger responses in participants with elevated baseline GluSph levels, alongside biomarker reductions linked to Parkinson’s disease biology.

• The update supports the broader Simply Wall St community narrative that Gain’s lead program could represent a differentiated disease-modifying Parkinson’s therapy, with valuation upside dependent on future clinical validation and Phase 2 execution.

Biomarker signals strengthen GT-02287’s Parkinson’s case

Gain Therapeutics (NASDAQ:GANX) presented new interim data from its ongoing Phase 1b study of GT-02287 at the 3rd International GBA1 Meeting 2026, adding further evidence that the company’s lead Parkinson’s disease candidate may be affecting underlying disease biology rather than simply managing symptoms.

The latest update covered participants enrolled in the study’s nine-month extension phase, where all 16 remaining participants have now completed 150 days of dosing. According to the company, MDS-UPDRS scores remained stable and durable across the overall study population during that period.

One of the more closely watched findings involved patients with elevated baseline levels of glucosylsphingosine (GluSph) in cerebrospinal fluid. These participants continued to show stronger responses compared to patients with lower GluSph levels, with a 4.8-point difference in combined MDS-UPDRS Part II and Part III scores at Day 150.

Gain also reported that GluSph levels declined by an average of 81% after 90 days of treatment among patients with elevated baseline levels. The biomarker is associated with glucocerebrosidase dysfunction, which has been linked to alpha-synuclein aggregation and neuronal damage in Parkinson’s disease.

Why GT-02287’s mechanism matters

GT-02287 is designed as an orally administered allosteric small molecule that restores the function of glucocerebrosidase (GCase), an enzyme that becomes impaired in Parkinson’s disease patients with GBA1 mutations and potentially in broader idiopathic Parkinson’s populations as well.

The therapeutic approach aims to address upstream biological dysfunction associated with Parkinson’s progression. In preclinical studies, GT-02287 demonstrated reductions in alpha-synuclein aggregation, neuroinflammation, mitochondrial dysfunction, and neuronal death, while also improving motor and gait performance in animal models.

Beyond biomarker data, Gain Therapeutics highlighted unsolicited patient feedback during the study. Participants most commonly reported improvements in smell and taste, balance or gait, and sleep quality. These observations appear to be influencing the design of the upcoming Phase 2 trial, where the company plans to formally evaluate several of these measures as secondary endpoints.

The company also plans to incorporate objective assessment tools, including the University of Pennsylvania Smell Identification Test and wearable gait sensors, into future clinical studies.

Early disease-modifying potential still faces clinical validation

For investors, the significance of the update lies less in near-term revenue implications and more in the evolving clinical profile of GT-02287.

Parkinson’s disease remains a large unmet medical need, particularly for therapies capable of slowing or halting disease progression rather than only treating symptoms. While several companies are pursuing disease-modifying approaches, demonstrating durable clinical benefit in neurodegenerative diseases has historically proven difficult.

Gain Therapeutics’ latest results may strengthen confidence that GT-02287 is engaging its intended biological targets. The alignment between biomarker reductions, stable MDS-UPDRS scores, and patient-reported functional improvements could support the broader disease-modification thesis the company is advancing.

At the same time, the current study remains relatively small and early-stage. Investors will likely want to see whether these signals persist in larger, placebo-controlled trials before assigning substantial commercial probability to the program.

Execution risk also remains significant. The company will need to successfully advance into Phase 2 development, confirm efficacy across broader Parkinson’s populations, and ultimately demonstrate clinically meaningful outcomes that regulators and physicians view as differentiated.

Parkinson’s drug development continues shifting toward biology-driven therapies

Gain Therapeutics’ update arrives amid increasing industry focus on therapies targeting the biological drivers of neurodegenerative disease.

Traditional Parkinson’s treatments largely focus on dopamine replacement and symptom management. More recent research efforts have shifted toward protein aggregation, lysosomal dysfunction, mitochondrial stress, and neuroinflammation as potential therapeutic targets.

GBA1-related biology has emerged as one of the more closely followed areas within Parkinson’s research, partly because GBA1 mutations represent the most common known genetic risk factor associated with the disease. Several biotechnology companies are now exploring enzyme restoration and lysosomal modulation approaches as potential disease-modifying strategies.

If GT-02287 continues to generate positive clinical data, Gain Therapeutics could position itself within this broader transition toward mechanism-driven neurodegenerative therapies.

Most followed narrative

The most followed Simply Wall St community narrative on Gain Therapeutics centers on the idea that GT-02287 could emerge as a differentiated disease-modifying therapy for Parkinson’s disease by targeting underlying lysosomal dysfunction rather than simply alleviating symptoms.

The narrative highlights the commercial potential of Parkinson’s therapies capable of slowing disease progression, particularly in both GBA1-mutated and idiopathic Parkinson’s populations. It also emphasizes the strategic importance of Gain’s Magellan™ platform and the company’s focus on allosteric small molecule therapies.

The narrative’s valuation framework assumes successful progression through mid-stage clinical development and eventual commercialization potential within a large global Parkinson’s market. The author argues that biomarker validation and durable functional improvements would represent critical milestones supporting future valuation expansion.

This week’s update appears to support parts of that thesis by showing continued biomarker engagement, stable MDS-UPDRS scores, and emerging signals in functional areas such as gait, sleep, and smell perception. However, the investment case still depends heavily on successful Phase 2 execution and larger-scale efficacy validation.

Read the full investment case for Gain Therapeutics.

What investors may watch next

Investors will likely monitor several key milestones over the coming quarters:

1. The design and initiation timeline of the planned Phase 2 trial
2. Whether biomarker reductions continue translating into measurable clinical outcomes
3. Additional durability data from the ongoing Phase 1b extension study
4. Expansion of efficacy signals beyond GBA1-related Parkinson’s populations
5. Regulatory interactions and future development funding needs

About the company

Gain Therapeutics (NASDAQ:GANX) is a clinical-stage biotechnology company developing allosteric small molecule therapies for neurodegenerative, metabolic, and rare diseases. Its lead program, GT-02287, is currently being evaluated in clinical studies for Parkinson’s disease with or without a GBA1 mutation.

Simply Wall St analyst Mitch Lawler and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.